MICHELLE LEMON: Open Payments
NPI 1871631184 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$839 in 43 payments from 12 companies in 2025. Trend: 2023 $2,517 · 2024 $1,810 · 2025 $839
Food & beverage: $839
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 15 | $237 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $169 |
| Teva Pharmaceuticals USA, Inc. | 4 | $92 |
| Otsuka America Pharmaceutical, Inc. | 4 | $92 |
| Collegium Pharmaceutical, Inc. | 4 | $79 |
| Noven Therapeutics, LLC | 2 | $41 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $24 |
| Alkermes, Inc. | 1 | $21 |
| Neos Therapeutics, LP | 1 | $17 |
Products named: INVEGA SUSTENNA, CAPLYTA, ABILIFY MAINTENA, Jornay PM, AUSTEDO XR, Xelstrym, Sunosi, VIVITROL.
Industry payments across NE — which companies pay providers there.
